English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

For several decades, in breast cancer patients with a luminal subtype, tamoxifen has been the main endocrine therapy in adjuvant setting in both pre- and postmenopausal women. However, it may be suboptimal in some premenopausal patients. The results of prospective, randomised studies SOFT/TEXT clearly demonstrated that the combination of OFS with TAM or IA is more effective than monotherapy TAM in breast cancer premenopausal women with hormone-sensitive early breast cancer and a high risk of recurrence.

Tamoxifen — no longer a golden standard for adjuvant therapy in the treatment of premenopausal patients with hormone-sensitive breast cancer